The platelet, once thought to be solely involved in clot formation, is now known to be a key
mediator in various others processes such as inflammation, thrombosis, and atherosclerosis …

or resistant” has been used to describe selected patients, especially high-risk patients and
diabetics, exhibiting high platelet function as measured by assays that are nonspecific in …

Background—Whether triple antiplatelet therapy is superior or similar to dual antiplatelet
therapy in patients with acute ST-segment elevation myocardial infarction undergoing …

Objectives: We evaluated safety and efficacy of triple antiplatelet therapy with aspirin,
clopidogrel, or ticlopidine and cilostazol after coronary stenting. Background: Triple …

Aims Patients with type 2 diabetes mellitus (T2DM) have reduced platelet inhibition
compared with non-diabetics following P2Y12 receptor blockade. Whether inhibition of …

Objectives: The purpose of this study was to determine the impact of adjunctive cilostazol in
patients with high post-treatment platelet reactivity (HPPR) undergoing coronary stenting …

BACKGROUND: Cilostazol has been widely used to prevent peripheral vascular events, and
its antiplatelet mechanisms may different from aspirin and clopidogrel. We hypothesized that …

Summary Abstract Clopidogrel (Plavix®, Iscover®) selectively and irreversibly inhibits
adenosine diphosphate (ADP)-induced platelet aggregation. Long-term administration of …

BACKGROUND: Drug-eluting stents reduce the risk of restenosis after percutaneous
coronary intervention (PCI) but may pose a risk of thrombosis. Cilostazol, an oral antiplatelet …

To evaluate the impact of cilostazol on neointimal hyperplasia after drug-eluting stent (DES)
implantation for long coronary lesions, we performed a randomized multicenter prospective …